Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.
Company profile
Ticker
AMLX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Amylyx Pharmaceuticals Canada Inc. • Amylyx Pharmaceuticals EMEA B.V. • Amylyx Pharmaceuticals Distribution Ltd. • Amylyx Pharmaceuticals Germany GmbH • Amylyx Pharmaceuticals France SAS • Amylyx Pharmaceuticals Belgium SRL • Amylyx Pharmaceuticals UK Ltd. • Amylyx Pharmaceuticals Japan K.K. ...
IRS number
464600503
AMLX stock data
Latest filings (excl ownership)
8-K
Other Events
10 Apr 24
8-K
Cost Associated with Exit or Disposal Activities
4 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX
8 Mar 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
UPLOAD
Letter from SEC
20 Dec 23
CORRESP
Correspondence with SEC
19 Dec 23
8-K
Regulation FD Disclosure
7 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm | 135.98 mm |
Cash burn (monthly) | 37.50 mm | (no burn) | (no burn) | 19.00 k | 1.72 mm | 4.28 mm |
Cash used (since last report) | 250.03 mm | n/a | n/a | 126.68 k | 11.49 mm | 28.52 mm |
Cash remaining | -114.05 mm | n/a | n/a | 135.85 mm | 124.49 mm | 107.46 mm |
Runway (months of cash) | -3.0 | n/a | n/a | 7150.0 | 72.3 | 25.1 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 37 |
Closed positions | 17 |
Increased positions | 68 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 1.08 tn |
Total shares | 61.25 mm |
Total puts | 856.90 k |
Total calls | 954.37 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 5.05 mm | $92.47 bn |
BLK Blackrock | 3.58 mm | $65.47 bn |
Viking Global Investors | 2.96 mm | $54.24 bn |
Perceptive Advisors | 2.69 mm | $49.23 bn |
Stonepine Capital Management | 2.52 mm | $46.07 bn |
Morningside Venture Investments | 2.31 mm | $43.30 mm |
Millennium Management | 2.12 mm | $38.81 bn |
Boxer Capital | 2.08 mm | $38.16 bn |
Avidity Partners Management | 1.76 mm | $32.17 bn |
Adage Capital Partners GP, L.L.C. | 1.70 mm | $31.13 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | James M Frates | Common Stock | Grant | Acquire A | No | No | 0 | 91,180 | 0.00 | 225,964 |
16 Apr 24 | James M Frates | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 120,000 | 241.20 k | 120,000 |
16 Apr 24 | Joshua B Cohen | Common Stock | Grant | Acquire A | No | No | 0 | 179,850 | 0.00 | 3,202,852 |
16 Apr 24 | Joshua B Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 380,000 | 763.80 k | 380,000 |
16 Apr 24 | Gina Mazzariello | Common Stock | Grant | Acquire A | No | No | 0 | 80,560 | 0.00 | 161,932 |
16 Apr 24 | Gina Mazzariello | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 110,000 | 221.10 k | 110,000 |
16 Apr 24 | Justin B. Klee | Common Stock | Grant | Acquire A | No | No | 0 | 179,850 | 0.00 | 3,139,158 |
16 Apr 24 | Justin B. Klee | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 380,000 | 763.80 k | 380,000 |
16 Apr 24 | Camille L Bedrosian | Common Stock | Grant | Acquire A | No | No | 0 | 96,910 | 0.00 | 155,243 |
16 Apr 24 | Camille L Bedrosian | Stock Option Common Stock | Grant | Acquire A | No | No | 2.01 | 120,000 | 241.20 k | 120,000 |
News
Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
11 Apr 24
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
11 Apr 24
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
10 Apr 24
Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
10 Apr 24
Amylyx Pharmaceuticals To Host Virtual Webcast To Discuss Interim Data From Phase 2 HELIOS Study Of AMX0035 In Wolfram Syndrome On April 10, 2024
8 Apr 24
Press releases
Investigation Alert Amylyx, Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLP
15 Apr 24
DEADLINE ALERT for XPOF, LUXH, and AMLX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
9 Apr 24
The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
9 Apr 24
Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline
8 Apr 24
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
8 Apr 24